Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.885
-0.055 (-2.84%)
Oct 8, 2026, 12:18 PM EDT - Market open
Inhibikase Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
343.21M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 260.50K | 137.06K | 111.03% |
| Dec 31, 2022 | 123.44K | -2.98M | -96.02% |
| Dec 31, 2021 | 3.10M | 2.40M | 343.92% |
| Dec 31, 2020 | 698.47K | -424.27K | -37.79% |
| Dec 31, 2019 | 1.12M | -2.92M | -72.22% |
| Dec 31, 2018 | 4.04M | 1.98M | 96.07% |
| Dec 31, 2017 | 2.06M | 1.09M | 113.04% |
| Dec 31, 2016 | 967.39K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| Enanta Pharmaceuticals | 65.26M |
| Fennec Pharmaceuticals | 59.22M |
| C4 Therapeutics | 35.04M |
| Orchestra BioMed Holdings | 31.98M |
| Arcturus Therapeutics Holdings | 29.37M |
| Ocugen | 4.58M |
| Artiva Biotherapeutics | 251.00K |
IKT News
- 5 days ago - Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Inhibikase Therapeutics Slides: Corporate presentation - Filings
- 1 month ago - Inhibikase Therapeutics reports Q2 EPS (11c), consensus (9c) - TheFly
- 1 month ago - Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 1 month ago - Inhibikase Therapeutics Earnings release: Q2 2026 - Filings
- 1 month ago - Inhibikase Therapeutics Quarterly report: Q2 2026 - Filings
- 2 months ago - Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA - TheFly
- 2 months ago - Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH - GlobeNewsWire